5 results about "Triglyceride synthesis" patented technology

This invention provides the application of a *Breago brevis* strain in the preparation of products that promote intramuscular fat deposition in livestock and poultry. The *Breago brevis* strain is *Breago brevis* JCM 32280. Under high-fiber dietary conditions, supplementation with *Breago brevis* JCM 32280 of this invention can efficiently degrade fiber to produce high concentrations of butyrate. Butyrate, as a key effector molecule, can directly bind to and activate PPARγ receptors in host cells, thereby upregulating the MOGAT2-mediated triglyceride synthesis pathway, significantly increasing body fat percentage in mammals and promoting intramuscular fat (marbling). Simultaneously, this strain can reshape the intestinal microecology, specifically increasing the abundance of beneficial intestinal lactobacilli and enhancing the intestinal mucus barrier, providing a safe and efficient microbial preparation strategy for improving the fat deposition capacity and meat flavor of livestock and poultry.

The application belongs to the technical field of medicine, and relates to application of X201415 acting on GPR75 protein in preparation of a medicine for treating non-alcoholic fatty hepatitis. Experiments show that the lipid-lowering effect of X201415 in liver cells is exerted through GPR75 protein. After X201415 treatment, the liver morphology of mice is improved, the body weight and liver index of the mice are reduced, and the TC and TG contents of the liver are significantly reduced in CDAHFD-induced NASH mice; in addition, the epididymal fat volume is also significantly reduced. Liver histology shows that X201415 can effectively improve lipid metabolism disorder and the degree of fibrosis, make the liver lobule arrangement more orderly, reduce fat accumulation and collagen fibers; down-regulate the expression level of lipid metabolism related genes, and inhibit the synthesis of fatty acid and triglyceride. At the same time, X201415 significantly inhibits the expression of inflammation factor genes and fibrosis related genes, which reflects the potential efficacy of the medicine in regulating the process of inflammation and fibrosis. The application provides experimental basis and ideas for synthesis of X201415, new targets and application of X201415 in NASH.

The invention relates to the technical field of molecular biology, in particular to an MUC15 gene segment, expression vector construction of the MUC15 gene segment and an expression vector transfection method of the MUC15 gene segment, and the nucleotide sequence of the MUC15 gene segment influencing buffalo mammary epithelial cell triglyceride and fatty acid synthesis is shown as SEQ No.1. The MUC15 gene segment is obtained by amplifying a primer pair, and the primer pair is used for amplifying the buffalo mammary epithelial cell triglyceride and fatty acid synthesis. The primer pair is specifically as follows: F: 5 '-AGTCCGGACTCAGATCTCGAGATGTTGACTCAGCCAAAATTCTG-3', F: 5 '- And R: 5 '-AATTCGAAGCTTGAGCTCGAGCTTACACGAAGTGGAGG-3'. Compared with the prior art, the buffalo mammary epithelial cell MUC15 gene fragment influencing the synthesis of triglyceride and fatty acid in the buffalo mammary epithelial cell is obtained, and a pEGFP-C1-MUC15 eukaryotic expression vector is constructed and transfected to the buffalo mammary epithelial cell, so that the synthesis of triglyceride by the buffalo mammary epithelial cell is promoted, and the milk fat content in buffalo milk is increased.

The invention relates to the technical field of treatment of neurodegenerative diseases, in particular to application of a DGAT1 specific oral inhibitor in neurodegenerative diseases, and the DGAT1 specific oral inhibitor is used for treating pathological tau protein related neurodegenerative diseases including Pick disease (PiD), Alzheimer's disease (AD), progressive suprakaryotic paralysis (PSP), cortical basal degeneration (CBD), silver granulopathy (AGD), familial tau proteopathy and the like. According to the application of the DGAT1 specific oral inhibitor in the treatment of the tau protein disease, the DGAT1 inhibitor is PF-04620110 (DGAT1 specificity) or PF-06865571 (DGAT1 and DGAT2 specificity). According to the application of the DGAT1 specific oral inhibitor in neurodegenerative diseases, the DGAT1 inhibitor can effectively penetrate through a blood-brain barrier through oral administration, the activity of a key enzyme DGAT1 for synthesizing triglyceride in glial cells is specifically inhibited, then abnormal accumulation of lipid droplets in the glial cells can be remarkably reduced through the targeted inhibition effect, and the DGAT1 specific oral inhibitor can be applied to neurodegenerative diseases. The normal physiological function is recovered.

The invention relates to a yeast engineering bacterium for synthesizing polyunsaturated fatty acid conjugated phospholipid as well as a construction method and application thereof, and belongs to the technical field of microbial engineering.The engineering bacterium takes yarrowia lipolytica as a chassis cell, and Mhy1, Iro1, IDH1 and CEX1 genes participating in hypha generation, triglyceride synthesis, citric acid metabolism and citric acid excretion are knocked out from a genome of the yarrowia lipolytica; the construction method comprises the following steps: sequentially connecting CDS1, OPI3, Mce2, LplA, 9Elo, 8Des, 5Des, 17Des, 5Elo, 15Des and LPCAT3 genes of acyltransferase, so as to form an expression module which is integrated at a URA site of a genome. The construction method comprises the following steps of: synthesizing phospholipids, synthesizing pyruvic acid, synthesizing polyunsaturated fatty acid, and sequentially connecting CDS1, OPI3, Mce2, LplA, 9Elo, 8Des, 5Des, 17Des, 5Elo, 15Des and LPCAT3 genes of acyltransferase. The polyunsaturated fatty acid combined phospholipid is efficiently obtained in one step through the yeast engineering bacteria, the phospholipid yield is 151.19 mg / g, and the EPA content in combined fatty acid is 13.2%.